Addressing the global impact of rheumatology research: preface to the Viewpoint Series in EULAR Rheumatology Open on the progress in international rheumatology Authors: Gerd R Burmester Published: 2026 Science is global, as is the impact of rheumatic and musculoskeletal diseases (RMDs). Progress in our field depends on international research and collaboration, values that are central to EULAR’s mission. Our new journal, EULAR Rheumatology Open, is proud to launch a series of articles highlighting rheumatology in different regions of the world. This series follows the earlier landmark contribution in RMD Open with Yoshiya Tanaka’s article on the development and achievements of Japanese rheumatology [1]. Now, we are delighted to begin in China, with the article ‘From “Me too” to “Me better” and “Me cooler”: the recent rheumatology advances in China’, authored by Wenwen Xu and Shuang Ye from Shanghai [2]. This viewpoint provides a timely overview of the rapid evolution of Chinese rheumatology in the recent past. The authors describe how Chinese researchers are moving from ‘Me Too’ validation studies to ‘Me Better’ strategies and ‘Me Cooler’ innovations, repurposing existing tools to tackle unmet clinical needs. Key highlights include rheumatoid arthritis with landmark trials of new JAK inhibitors, biosimilars, and digital health interventions, as well as systemic lupus erythematosus, influencing EULAR and the KDIGO foundation (‘Kidney Disease: Improving Global Outcomes’) recommendations and addressing novel approaches such as telitacicept and chimeric antigen receptor T cell (CAR-T) therapies. In myositis and systemic sclerosis, real-world studies are shaping international guidelines and expanding collaborations. Regarding other autoimmune diseases, advances in immunoglobulin G4-related disease, polymyalgia rheumatica, and novel approaches to fibrotic disorders are targeted. Together, these advances demonstrate China’s growing rheumatology research, supported by large-scale trial capacity, regulatory reform, and integration of translational science with clinical research. The article underlines how China is positioning itself as a key contributor to global rheumatology innovation. When people in Europe think about medicine in China, their first association is often with traditional Chinese medicine. Within China itself, however, there seems to be a noticeable divide between long-established traditional approaches and modern ‘Western medicine.’ Many of us who have had the opportunity to visit China and tour its advanced rheumatology units have gained a feeling of the differences between Chinese and Western perspectives on disease—its origins, its manifestations, and the ways these understandings shape treatment approaches. Such cultural differences are not only important to recognise but also offer opportunities for reflection on what each tradition might contribute to the other. Expanding future viewpoint articles to consider how we could learn from these diverse perspectives would therefore be of real value. At present, medical training and exchange in China, as in many other parts of the world, tend to focus almost exclusively on ‘Western’ rheumatology. Future contributions in this series could usefully broaden the discussion, situating rheumatology within its wider cultural and medical context. As history has shown—from early immunology breakthroughs such as Shibasaburo Kitasato’s work with Emil von Behring [3] to the global rheumatology community’s joint response to the COVID-19 pandemic [4]—our discipline thrives through international exchange. By showcasing perspectives from China and, in the future, with subsequent articles from many other countries and regions, EULAR Rheumatology Open aims to highlight the global achievements shaping our field. Competing interests All authors declare they have no competing interests. REFERENCES